医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ResolutionMD® Medical Imaging Software Now Registered for Web and Mobile Diagnosis in Singapore

2015年08月12日 PM09:30
このエントリーをはてなブックマークに追加


 

CALGARY, Alberta

Calgary Scientific Inc., a company known for creating innovative technology for the medical industry and beyond, announced today that ResolutionMD® medical imaging software is now registered with the Health Sciences Authority (HSA) in Singapore for diagnosis using both web and mobile devices. This certification enables medical practitioners in Singapore to provide a higher standard of care by gaining quick, secure mobile access to diagnostic images using ResolutionMD® with their web, iOS or Android devices.

Obtaining registration from the HSA means that ResolutionMD®, the world’s leading enterprise image-viewing solution can now be sold and used in Singapore. The registration follows ResolutionMD’s FDA Class II clearance in the US, CFDA certification in China, PDMA certification in Japan, MDCO certification in Hong Kong, MFDS registration in Korea, CE marking in Europe, TGA certificate in Australia and Health Canada license.

“Obtaining this registration in Singapore is another significant milestone for Calgary Scientific,” said Pierre Lemire, CTO and EVP, Products at Calgary Scientific. “We are seeing great demand for ResolutionMD® throughout Asia as the clinical adoption of mobile devices continues to grow at a significant pace. I am very pleased that healthcare providers in Singapore can now leverage our fully accredited web and mobile solution to get faster image access resulting in better patient care.”

For more information on accreditations, visit www.calgaryscientific.com/accreditation

About ResolutionMD®

ResolutionMD enables doctors to securely view patient images and reports from a wide variety of computers and mobile devices, collaborate with other practitioners and diagnose from any location. Whether you are a single facility or a large healthcare system with tens of thousands of users, ResolutionMD is the best choice for seamless image access across multiple departments. ResolutionMD is globally accredited by the FDA, CFDA, TGA, PMDA, MDCO, MFDS, HSA, CE and Health Canada for mobile medical diagnosis. The software can be integrated into any EMR and easily plugs into existing distributed storage systems. ResolutionMD’s federated approach is an important differentiator from other solutions as highly sensitive data is never moved to any device and no additional data storage locations are created. ResolutionMD is currently installed in leading healthcare institutions around the world via a network of more than forty-five world class healthcare partners. For more information, go to http://www.calgaryscientific.com/resolutionmd.

About Calgary Scientific Inc.

Calgary Scientific is the global leader in web and mobile diagnostic medical imaging and cloud enabling solutions. For more information on Calgary Scientific, go to www.calgaryscientific.com.

© 2015 Calgary Scientific Inc., ResolutionMD, PureWeb and the Calgary Scientific logo are trademarks and/or registered trademarks of Calgary Scientific Inc. or its subsidiaries. Any third-party company names and products are for identification purposes only and may be trademarks of their respective owners.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150812005037/en/

CONTACT

Calgary Scientific Inc.
Jennifer Sobotka, (+1) 403-767-7941
Director
of Marketing
Jennifer.Sobotka@calgaryscientific.com
or
Investor
contact:

Byron Osing, (+1) 403-767-7959
CEO and Chair
Byron.Osing@calgaryscientific.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続